Table 1.
Laboratory and clinical characteristics of the patients and control subjects included in the study
| Characteristics | All SSc (n = 31) | Non-ILD-SSc (n = 10) | SSc-ILD (n = 21) | Other CTD (n = 10) | HC (n = 20) |
|---|---|---|---|---|---|
| Age (mean ± SD) | 51 ± 13 | 49 ± 14 | 53 ± 12 | 47 ± 11 | 40 ± 11 |
| Female,n(%) | 27 (87) | 10 (91) | 17 (85) | 8 (80) | 17 (85) |
| Course of disease (mean ± SD) | 8 ± 7 | 8 ± 8 | 9 ± 8 | NA | |
| lSSc/dSSc % | 55/45 | 45/55 | 60/40 | ||
| PAH,n(%) | 3 (10) | 0 (0) | 3 (15) | ||
| Raynaud’s phenomenon,n(%) | 28 (90) | 9 (82) | 19 (45) | ||
| Anti-Scl-70 antibody,n(%) | 13 (42) | 4 (36) | 9 (45) | ||
| ANA,n(%) | 30 (97) | 10 (91) | 20 (100) | ||
| Anti-RNP,n(%) | 8 (26) | 4 (36) | 4 (20) | ||
| Anti-centromere,n(%) | 8 (26) | 2 (18) | 6 (30) | ||
| mRSS (mean ± SD)n = 25 | 12 ± 10 | 21 ± 14 | 10 ± 7 | ||
| Immunosuppressive therapy ever,n(%) | 11 (35) | 5 (45) | 6 (25) | ||
| Cyclophosphamide,n(%) | 6 (19) | 3 (27) | 3 (15) | ||
| Methotrexate,n(%) | 2 (6) | 0 (0) | 2 (5) | ||
| Mycophenolate mofetil,n(%) | 3 (10) | 2 (18) | 1 (5) | ||
| FVC % predicted,n = 17 (mean ± SD) | 74.5 ± 14.2 | 78 ± 8.5 | 75.6 ± 16.2 | ||
| DLCO% predicted,n = 8 (mean ± SD) | 74.2 ± 22.3 | 70.9 ± 3.5 | 76.2 ± 27.8 | ||
| FEV1/FVC%,n = 17 (mean ± SD) | 85.5 ± 11.6 | 76.2 ± 7.5 | 88.4 ± 11.1 | ||
| ESR, mm/h (mean ± SD) | 17.10 ± 11 | 17.80 ± 14.36 | 16.76 ± 9.13 | ||
| PLT, 109/L (mean ± SD) | 206 ± 67 | 209.40 ± 79.98 | 204.62 ± 61.60 | ||
| MPV, fL (mean ± SD) | 11.95 ± 1.49 | 11.23 ± 1.95 | 10.81 ± 1.24 | ||
| PDW, fL (mean ± SD) | 0.22 ± 0.07 | 0.23 ± 0.08 | 0.22 ± 0.07 | ||
| PCT, % (mean ± SD) | 31.17 ± 11.13 | 34.69 ± 14.07 | 29.49 ± 9.36 | ||
| P-LCR, % (mean ± SD) | 13.47 ± 3.30 | 14.12 ± 4.50 | 13.16 ± 2.63 | ||
| RA,n(%) | NA | 1 (10) | NA | ||
| ANCA-associated vasculitis,n(%) | 1 (10) | ||||
| SLE,n(%) | 2 (20) | ||||
| SS,n(%) | 1 (10) | ||||
| Dermatomyositis,n(%) | 2 (20) | ||||
| Polymyositis,n(%) | 3 (30) | ||||
Abbreviations: SSc systemic sclerosis, ILD interstitial lung disease, PAH pulmonary arterial hypertension, CTD connective tissue diseases, HC healthy control subjects, SD standard deviation, dSSc diffuse cutaneous systemic sclerosis, lSSc limited cutaneous systemic sclerosis, ANA antinuclear antibodies, anti-RNP anti-ribonucleoprotein antibody, mRSS modified Rodnan skin score, FVC forced vital capacity, DLCO diffusing capacity of the lung for carbon monoxide, FEV1 forced the first second of expiratory volume, ESR erythrocyte sedimentation rate, PLT platelet count, PDW platelet distribution width, PCT plateletcrit, MPV mean platelet volume, P-LCR platelet large cell ratio, RA rheumatoid arthritis, ANCA anti-neutrophil cytoplasmic antibodies, SLE systemic lupus erythematosus, SS Sjogren syndrome, NA not available